TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
GRAL

GRAIL, LLC

Healthcare · Diagnostics & Research

154.10$ +7.6% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GRAL
Line item 2018 2019 2020 2021 2022 2023 2024 2025
– -7.5% +11.1% +1,278.7% -42.5% -18.7% -34.5% -2.1%
– -14.1% +6.9% -59.3% +21.8% -47.2% +425.3% +16.3%
– +50.6% +18.9% +29.9% +9.2% -59.7% +120.2% +16.6%
– -15.1% +7.2% -62.1% +9.2% -59.7% +684.8% +18.5%
– – – – +170.5% +20.1% +10.2% -25.8%
– – – – – +9.8% -14.1% -14.0%
– – – – -75.8% -40.6% -100.0% –
– – – – -4.5% -8.5% -24.9% -8.2%
– -1.7% +70.0% +112.8% +211.0% -4.7% -47.3% -28.3%
– -39.4% +86.9% +16.6% +37.9% +21.2% -53.0% +3.6%
– +213.3% +0.8% +153.4% -3.4% +11.1% -10.5% -11.7%
– -52.3% +302.6% -28.0% -0.9% +12.5% -75.4% -57.0%
– -8.3% +2.1% +1,578.5% -50.7% -21.5% -31.3% +3.0%
– – – – – – – –
– +7.9% +0.4% -74.9% +0.0% +0.0% +2.7% +15.2%

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?